相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Measured Human Dosimetry of 68Ga-DOTATATE
Ronald C. Walker et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
Renzo Cescato et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Flavio Forrer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours
GA Kaltsas et al.
ANNALS OF ONCOLOGY (2001)